Last reviewed · How we verify

NCT03929458

Association of Uremic Sarcopenia and Mitochondrial Copy Number and Its Clinical Correlates

Completed Last updated 11 March 2020
What this trial tests

trial in Sarcopenia in 160 participants. Completed in 31 December 2019.

Timeline
7 May 2019
Primary endpoint
31 December 2019
31 December 2019

Quick facts

Lead sponsorTungs' Taichung Metroharbour Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment160
Start date7 May 2019
Primary completion31 December 2019
Estimated completion31 December 2019
Sites1 location across Taiwan

Conditions studied

Sponsor

Tungs' Taichung Metroharbour Hospital

Who can join

Adults 20 to 90, any sex, with Sarcopenia or Mitochondrial DNA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sarcopenia is the decline of muscle mass and strength with age. Evidence suggests that oxidative stress and molecular inflammation play important roles in age-related muscle atrophy. The two factors may interfere with the balance between protein synthesis and breakdown, cause mitochondrial dysfunction, and induce apoptosis. Sarcopenia, inflammation and oxidative stress is highly prevalent in hemodialysis patients and may contribute to mortality. The copy number of mitochondrial DNA (mtDNA) is affected by oxidative stress in blood circulation. This study aimed to test whether mtDNA copy number correlates with oxidative stress and some uremic toxins in nondiabetic hemodialysis(HD) patients. 200 nondiabetic hemodialysis patients and 50 healthy subjects will be enrolled. This study will be performed to investigate quantitative changes in mtDNA occur in HD patients with and without sarcopenia. Copy number of mtDNA in leukocyte DNA is determined by real-time polymerase chain reaction in HD patients and 50 age- and sex-matched control subjects. In addition, correlation of the alterations of albumin redox status, 8-isoprostane, plasma IL-6 ,LBP and TNF-a and as well as various uremic toxins will be performed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Mitochondrial VDAC1: A Potential Therapeutic Target of Inflammation-Related Diseases and Clinical Opportunities.
    Hu H, Guo L, Overholser J, Wang X. · · 2022 · cited 53× · PMID 36231136 · DOI 10.3390/cells11193174

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Other Tungs' Taichung Metroharbour Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929458.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing